Calorie restriction has been widely considered a promising approach to fostering long-term health and longevity [12]. In various organisms, from yeast to mammals, calorie restriction (with a significant reduction in food and caloric intake below ad libitum levels without causing malnutrition) has been found to be effective in increasing life span and delaying the onset of age-related diseases [13]. The molecular pathways underlying these benefits are complex and multifaceted, including reduced insulin and Insulin Growth Factor-1 (IGF-1) signaling, inhibiting the mechanistic target of rapamycin (mTOR) signaling, activation of AMP-activated protein kinase (AMPK) and sirtuins 1 (SIRT1), upregulation of the NAD+ pathway and autophagy, and reducing inflammation and oxidative stress [14, 15].
However, the effects of sustained calorie restriction over the long-term in humans are much more challenging to study, especially in the context of the obesogenic food environment [16]. In the longest caloric reduction trial among nonobese individuals, the Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) trial demonstrated that participants in the calorie restriction group achieved approximately 12% calorie reduction and a sustained 10% weight loss compared to the control group over 2 years, accompanied by significant improvement in blood lipids, blood pressure, insulin sensitivity, and pro-inflammatory cytokines [17]. Despite these promising findings, it is difficult to extrapolate the short-term cardiometabolic benefits to long-term chronic disease risk reduction and increased longevity due to the study’s relatively short duration and small sample size.
A major challenge in the practical implementation of calorie restriction lies in the accurate tracking of daily caloric intake, energy expenditure, and long-term adherence to a calorie-restricted diet. In epidemiologic studies, body weight trajectories can be used as a marker of long-term energy balance across different stages of life. Using data from NHS and HPFS, we assessed body shape trajectories in early and middle life in relation to subsequent mortality risk [18]. Using a statistical modeling approach, five distinct trajectories of body shape from age 5 to 50 were identified: lean-stable, lean-moderate/increase, lean-marked/increase, medium-stable/increase, and heavy-stable/increase. To minimize confounding by smoking, the primary analyses were limited to never smokers. Compared to the lean-stable group, the multivariable-adjusted hazard ratio for death from any cause was 1.08 (95% confidence interval 1.02–1.14) for women and 0.95 (0.88–1.03) for men in the lean-moderate/increase group, 1.43 (1.33–1.54) for women and 1.11 (1.02–1.20) for men in the lean-marked/increase group, 1.04 (0.97–1.12) for women and 1.01 (0.94–1.09) for men in the medium-stable/increase group, and 1.64 (1.49–1.81) for women and 1.19 (1.08–1.32) for men in the heavy-stable/increase group. This study provides evidence to support the benefits on longevity of maintaining a stable-lean body shape throughout life. Similarly, women and men who maintained a lean body shape across different life stages had the lowest risk of type 2 diabetes and CVD, whereas those who had substantially increased body adiposity had the highest risk of developing these diseases [19].
In further analyses, even a modest amount of weight gain (e.g., 5 kg) during young and middle adulthood (18–55 years) was associated with a significantly elevated risk of developing type 2 diabetes (by 30%), hypertension (by 14%), CVD (by 8%), obesity-related cancer (by 6%), and premature death (by 5%) [20] (Fig. 1). This amount of weight gain was also associated with 17% lower likelihood of achieving healthy aging defined as being free of major chronic conditions and having no substantial cognitive, physical, or mental limitations after age 55. Moreover, individuals with the body mass index (BMI) range of 18.5–22.4, combined with higher levels of physical activity and healthy diets had the lowest mortality, suggesting that leanness induced by healthy diet and lifestyle is optimal to promote longevity [21].
Fig. 1
Associations of weight gain from early to middle adulthood with risk of individual health outcomes. After adjustment for age at cohort recruitment (continuous), height (continuous), race (non-White or White), pack-years of smoking (never smokers; past smoker with <5, 5–20, or >20 pack-years; and current smoker with <5, 5–20, or >20 pack-years), regular aspirin use (yes or no), status of menopause and hormone therapy (women only: premenopausal, postmenopausal and never use, postmenopausal and current use, or postmenopausal and past use), parity (women only: nulliparous, 1, 2, 3, or ≥4 children), physical activity, alcohol consumption dietary qualify (alternative healthy eating index in quintiles), family history of respective diseases and weight at age of 18 years in women and at age of 21 years in men. Obesity-related cancer includes the esophagus (adenocarcinoma only), colon and rectum, pancreas, breast (after menopause, women only), endometrium (women only), ovaries (women only), prostate (advanced only, men only), kidney, liver, and gallbladder. aA composite healthy aging outcome was defined as being free of 11 chronic diseases and major cognitive or physical impairment. Expressed as odds ratio (95% CI) per 5-kg weight gain. Source: Reproduced with permission from Ref. [20]. Copyright (2017) American Medical Association. All rights reserved (superficially modified).
Given the impracticality of conducting long-term calorie restriction trials, to a certain extent, the analyses on life course body weight trajectories in relation to health outcomes resemble a natural experiment. Individuals who maintain a lifelong leanness through healthy diet and lifestyle practices tend to live longer and healthier lives, mimicking results one might expect from long-term calorie restriction studies. The fasting mimicking diet, designed to provide health benefits of fasting without total food abstinence, has demonstrated positive effects on weight loss and cardiometabolic risk factors in short-term trials [22, 23], though longer term data are needed.

Leave a Reply